The topics include the discussion of the applications in relation to metabonomics and gut microbiota in nutritional research, in health and disease and a review of future therapeutical, dysbiosis obesity and clinical applications. It also examines the translatability of systems biology approaches into applied clinical research and to patient health and nutrition.
The rise in multifactorial disorders, the lack of understanding of the molecular processes cancer cerebral maligno play and the needs for disease prediction in asymptomatic conditions are some of the many questions that system biology approaches are well suited to address.
Achieving this goal lies in our dysbiosis obesity to model and understand the complex web of interactions between genetics, metabolism, environmental factors and gut microbiota. Being the most densely populated microbial ecosystem on earth, gut microbiota co-evolved as a key component of human biology, essentially extending the physiological definition of humans.
Major advances in microbiome research have shown that dysbiosis obesity contribution of the intestinal microbiota to the overall health status of the host has been so far underestimated.
In many aspects, humans are not a complete and fully healthy organism without their appropriate microbiological components. Increasingly, scientific evidence identifies gut microbiota as a key biological interface between human genetics and environmental conditions encompassing nutrition. Microbiota dysbiosis obesity or variation in metabolic activity has been associated with metabolic deregulation e. Metabonomics and Gut Microbiota in Nutrition and Disease serves as a handbook for postgraduate students, researchers in life dysbiosis obesity or health sciences, scientists in academic and industrial environments working in application areas as diverse as health, disease, nutrition, microbial research and human clinical medicine.